SEC	Form	4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

issuer that is int	 of equity securities of ended to satisfy the nse conditions of Rule nstruction 10. 							
1. Name and Addr Climaco Joh	ess of Reporting Pe I <u>n M</u>	rson*	2. Issuer Name and Ticker or Trading Symbol <u>CNS Pharmaceuticals, Inc.</u> [CNSP]		ionship of Reporting Pers all applicable) Director	son(s) to Issuer 10% Owner		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024	X	Officer (give title below)	Other (specify below)		
C/O CNS PHA	RMACEUTICA	LS, INC.			Chief Executive Officer			
100 WEST LOOP SOUTH, SUITE 900			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	ndividual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street)						in One Reporting Person		
HOUSTON	ТХ	77027						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	ount (A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common stock	02/01/2024		Р		166,666	Α	\$0.3 ⁽¹⁾	215,676	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Warrant to purchase common stock	\$0.3	02/01/2024		А		166,666		02/01/2024	02/01/2029	Common Stock	166,666	(1)	226,867	D	
Series B Warrant to purchase common stock	\$0.3	02/01/2024		А		166,666		02/01/2024	10/01/2025	Common Stock	166,666	(1)	393,533	D	

Explanation of Responses:

1. The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

/s/ Christopher Downs, Attorney-02/05/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the